Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8356066 | 1.00 | SRD5A1 (0.46) | SRD5A1CYP2D6ALDH1A1MTNR1BACHE | |
| SCHEMBL8355719 | 1.00 | SRD5A1 (0.46) | SRD5A1CYP2D6ALDH1A1MTNR1BACHE | |
| SCHEMBL10444032 | 0.88 | SRD5A1 (0.44) | SRD5A1CYP2D6MTNR1BTRPV1HTR2A | |
| SCHEMBL2381148 | 0.83 | SRD5A1 (0.39) | SRD5A1CYP2D6ALDH1A1MTNR1BACHE | |
| SCHEMBL9827245 | 0.81 | SRD5A1 (0.46) | SRD5A1TRPV1HTR2AHTR2CNOTUM | |
| SCHEMBL8707542 | 0.81 | SRD5A1 (0.40) | SRD5A1CYP2D6MTNR1BTRPV1HTR2A | |
| SCHEMBL7796406 | 0.78 | SRD5A1 (0.46) | SRD5A1ALDH1A1MTNR1BACHETRPV1 | |
| SCHEMBL8716246 | 0.76 | PRCP (0.47) | SRD5A1CYP2D6HTR2AHTR2C | |
| SCHEMBL10444191 | 0.74 | HTR2C (0.49) | SRD5A1CYP2D6ACHEHTR2AHTR2C | |
| SCHEMBL3697223 | 0.72 | ALDH1A1 (0.42) | SRD5A1ALDH1A1ACHEMAOBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998049147-A1 | PREPARATION OF MIBEFRADIL III | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-05 | — | — | WO | claimed |
| WO-1998049149-A1 | PREPARATION OF MIBEFRADIL I | F. HOFFMANN-LA ROCHE AG (CH) | 1998-11-05 | — | — | WO | claimed |
| US-5811557-A | Preparation of mibefradil via an acetonitrile anion | ROCHE COLORADO CORPORATION (US) | 1998-09-22 | — | — | US | claimed |
| US-5808088-A | Preparation of mibefradil via an acetamide anion | ROCHE COLORADO CORPORATION (US) | 1998-09-15 | — | — | US | claimed |
| EP-3144296-A1 | DEUTERATED TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9273009-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140155444-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8575361-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8513434-B2 | Tetrahydronaphthalene derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013036434-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS T-TYPE CALCIUM CHANNEL BLOCKER | CONCERT PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120122944-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110237635-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-5808088-A | Preparation of mibefradil via an acetamide anion | ROCHE COLORADO CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5808088-A | Preparation of mibefradil via an acetamide anion | ROCHE COLORADO CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0787711-A2 | Process for the preparation of alpha,beta-unsaturated carboxylic acids | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-06 | — | — | EP | disclosed |
| EP-0177960-B1 | DERIVATIVES OF TETRAHYDRONAPHTHALENE, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | HOFFMANN LA ROCHE (CH) | 1991-03-20 | — | — | EP | disclosed |
| CN-1007727-B | PROCESS FOR THE PREPARATION OF TETRAHYDRONAPHTALINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1990-04-25 | — | — | CN | disclosed |
| US-4680310-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-07-14 | — | — | US | disclosed |
| CN-85107496-A | The method for preparing tetrahydronaphthalenderivatives derivatives | — | 1986-07-23 | — | — | CN | disclosed |
| EP-0177960-A2 | Derivatives of tetrahydronaphthalene, process and intermediates for their preparation and medicines containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155444-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1H, CACNA1I, CACNA1G | SRD5A1 1128/4885CYP2D6 853/4885ALDH1A1 1369/4885 |
| US-20120122944-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1H, CACNA1I, CACNA1G | SRD5A1 1128/4885CYP2D6 853/4885ALDH1A1 1369/4885 |
| US-20110237635-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1H, CACNA1I, CACNA1G | SRD5A1 1128/4885CYP2D6 853/4885ALDH1A1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.